Techpool Bio-Pharma Co., Ltd.
8
1
1
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.5% vs industry average
50%
4 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Treatment of Acute Ischemic StroKe With Intravenous UroKinase Real-world Research: a Multicenter, Prospective Study
Role: collaborator
Ulinastatin Treatment in Adult Patients With Sepsis and Septic Shock in China
Role: collaborator
Post-market Safety Reassessment of Ulinastatin for Injection
Role: lead
The Safety and Dose Response Relationship of Ulinastatin for Acute Respiratory Distress Syndrome(ARDS)
Role: lead
Ulinastatin in Severe Acute Pancreatitis
Role: lead
Ulinastatin Injection in in Pediatric Patients Undergoing Open Heart Surgery
Role: lead
The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein
Role: lead
Chinese Acute Ischemic Stroke Treatment Outcome Registry
Role: collaborator
All 8 trials loaded